



**WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTE**

**WHO/BS/03.1971
English Only**

**EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION
Geneva, 17 to 21 November 2003**

**INTERNATIONAL COLLABORATIVE STUDY
Evaluation of a Candidate Replacement International Standard Preparation for
Anti-Toxoplasma Serum, Human**

Peter Rigsby¹, Sjoerd Rijpkema², Edward C Guy³ and Rose Gaines Das¹

¹Informatics Laboratory and ²Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG, and ³Toxoplasma Reference Laboratory, National Public Health Service for Wales, Swansea, SA2 8QA, United Kingdom.

Correspondence to:

Dr S Rijpkema, Division of Bacteriology, NIBSC, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, United Kingdom: Tel: +44 1707 641 000; Fax: +44 1707 663 796

E-mail: srijpkem@nibsc.ac.uk

Summary

A freeze-dried human serum preparation 01/600 containing antibodies to *Toxoplasma gondii* was assessed for its suitability as an international reference reagent in an international collaborative study by 24 laboratories from 17 countries. This candidate standard was compared with the third International Standard for Anti-Toxoplasma Serum, Human (TOXM), with samples of the previous second International Standard (TOXS), and with a range of other serum samples. Samples were tested in the Sabin-Feldman dye test and a range of agglutination and enzyme immunoassay-based tests. On the basis of the results of this study it is recommended that candidate preparation 01/600 be established as the fourth International Standard for Anti-Toxoplasma Serum, Human with an assigned potency of 20 IU per ampoule of total anti-toxoplasma antibodies.

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.